SCA
TVTX icon

SAC Capital Advisors’s Travere Therapeutics TVTX Stock Holding History

SAC Capital Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,932
Closed -$84K – 958
2014
Q1 		$84K Buy
+3,932
New +$60.5K ﹤0.01% 1681

Other funds holding TVTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAC Capital Advisors's TVTX Position: Q2 2014 in Review

SAC Capital Advisors sold out of Travere Therapeutics (TVTX) in Q2 2014, closing a stake of 3,932 shares — an estimated $84K sold.

SAC Capital Advisors first reported a position in TVTX in Q1 2014 and held it in 1 quarter. The position peaked at $84K in Q1 2014. 59 funds tracked by Wall St. Rank hold TVTX as of Q2 2014.

  • SAC Capital Advisors reported no remaining Travere Therapeutics position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 3,932 Travere Therapeutics shares in Q2 2014, an estimated $84K.
  • SAC Capital Advisors first reported a position in Travere Therapeutics in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Travere Therapeutics position peaked at $84K in Q1 2014.
  • 59 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.